Y-mAbs Therapeutics (YMAB) Misses Q1 EPS by 1c ; Offers Guidance

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q1 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $19.93 million versus the consensus estimate of $22.84 million.

GUIDANCE:

Y-mAbs Therapeutics sees FY2024 revenue of $95-100 million, versus the consensus of $96.87 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Rivian raises 2026 delivery outlook after Q2 results top guidance
• Lucid reports Q2 output, names new CFO and five other leaders